HVTN 083

Status:Completed
Phase:I
Principal Investigator(s):Xia Jin, MD, PhD
Objective:To evaluate the safety and immune response of an adenovirus-based HIV-1 vaccine regimen that includes two vaccines given at different time points in HIV-uninfected adults. last updated March 30, 2021
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Placebo, Randomized
Arms and Assigned Interventions
DescriptionrAd35 Env A vaccine at baseline and the rAd5 Env A vaccine at Month 3.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionrAd35 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionrAd35 Env A vaccine at baseline and at Month 3.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionrAd5 Env A vaccine at baseline and at Month 3.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionrAd5 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
Mode of DeliveryIntramuscular
ARMsExperimental
Results: Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083
Official Code: NCT01095224
Related Publications:
CD8+ T cell efficacy in vaccination and disease
Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1)
Trial Sponsors: NIAID
Start Date
End Date
October 31, 2010
March 30, 2016
Enrollment:180
Age range: 18 Years ↔ 50 Years
Population:Cisgender Men, Cisgender Women